Isolated penile ulceration after Nivolumab therapy for non-small cell lung carcinoma

Immune-related cutaneous events can develop after immunotherapy. To our knowledge, we present the first reported case of isolated focal penile inflammatory ulceration in a patient being treated with Nivolumab for stage IV non-small cell lung carcinoma. He presented with a painless penile ulceration...

Full description

Saved in:
Bibliographic Details
Published in:Urology case reports 2020-11, Vol.33, p.101339, Article 101339
Main Authors: Baaklini, Gina T., Thompson, Misty J., Krauland, Kevin J., Walker, Daniel R., Hudak, Steven J.
Format: Article
Language:English
Subjects:
Drug eruption
Immunotherapy
Inflammation and Infection
Nivolumab
Penile ulceration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune-related cutaneous events can develop after immunotherapy. To our knowledge, we present the first reported case of isolated focal penile inflammatory ulceration in a patient being treated with Nivolumab for stage IV non-small cell lung carcinoma. He presented with a painless penile ulceration two months after initiating therapy. He had near-complete resolution of his ulcer after two weeks of topical treatment. Histologic evaluation revealed a drug eruption. While cutaneous events are a well-known side effect of immunotherapy, this is the first report of an isolated penile lesion from such therapy.
ISSN:2214-4420
2214-4420
DOI:10.1016/j.eucr.2020.101339